Home | Cardiovascular Business

The mitral valve seen on 3D cardiac ultrasound offers a noninvasive surgeon's view of the valve for better diagnostics and pre-planning of structural heart procedures.

In a new interview, former ACC and ASE President William A. Zoghbi, MD, reviews some of the biggest trends in cardiac ultrasound.

Read more about Q&A: William Zoghbi breaks down the future of echocardiography

The SGLT2 inhibitor, already approved for some high-risk heart failure patients, has now received a much wider approval.

Read more about FDA approves empagliflozin for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

Myocarditis as seen on cardiac MRI in patients who recently received COVID-19 messenger RNA vaccination from a November 2021 imaging study. Image courtesy of the American Journal of Roentgenology (AJR)

Waiting a few additional weeks, the agency wrote, could help limit myocarditis or pericarditis among young adults.

Read more about New CDC guidance: Waiting longer between COVID-19 vaccine doses could reduce risk of heart damage

The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. The results of the COAPT trial dropped like a thunderclap Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, with several cardiologists predicting the MitraClip device will have a swift and lasting impact on the treatment of heart failure patients.

The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. Image courtesy of Abbott.

The new analysis focused on both primary and secondary MR 12 months after TEER.

Read more about Recurrent MR after TEER: Tracking data from nearly 700 MitraClip patients

The team's findings, one researcher said, "could eventually make a huge impact on many patients lives."

Read more about Cardiologists identify 162 genes responsible for coronary heart disease

A team of researchers at Gladstone, including Bárbara González Terán shown here seated, developed a novel algorithm method for identifying genetic variants that are likely to play important roles in congenital heart disease. This opens up opportunities to accelerate research into this serious condition. Photo by Michael Short/Gladstone Institutes

A team of researchers at Gladstone, including Bárbara González Terán (seated), developed a novel algorithm method for identifying genetic variants that are likely to play important roles in congenital heart disease. This opens up opportunities to accelerate research into this serious condition. Photo by Michael Short/Gladstone Institutes

Researchers at Gladstone Institutes developed a new algorithm method for identifying genetic variant combinations that are likely to play important roles in congenital heart disease.

Read more about Algorithm helps sort genetic data to improve our understanding of congenital heart disease

The medication, originally developed to treat celiac disease, could provide significant relief for young MIS-C patients.

Read more about A potential new treatment for COVID-19 patients with MIS-C

Researchers focused on 30-day outcomes, sharing their findings in the American Journal of Cardiology.

Read more about Amyloidosis patients can safely undergo TAVR

Fruits vegetableshave been seen as a key component to heart health diets.

Don't give up on eating vegetables quite yet—but a new analysis in Frontiers in Nutrition does suggest they can't protect you from CVD all on their own.

Read more about Eating vegetables does little to prevent cardiovascular disease

Continuous and high-adherent statin users had lower baseline arterial stiffness which also grew more slowly over time, a new JAMA Network Open study finds.

The public comment period for these recommendations ends on March 21.

Read more about USPSTF shares updated recommendations on statin use to prevent CVD